RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q1 FY24 results · Apr–Jun 2023
RPG Life Sciences reported revenue from operations of ₹147.78 crore (up 14.6% from Q1 FY23) and net profit of ₹22.10 crore (up 21.4% from Q1 FY23) for Q1 FY24 (Apr–Jun 2023), on a standalone basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 147.78 | 128.93 | +14.6% | 118.49 | +24.7% |
| Other income | 1.81 | 1.22 | +48.4% | 1.84 | −1.6% |
| Total income | 149.59 | 130.15 | +14.9% | 120.33 | +24.3% |
| Profit before tax | 29.77 | 25.12 | +18.5% | 13.81 | +115.6% |
| Net profit for the period | 22.10 | 18.21 | +21.4% | 10.35 | +113.5% |
| EPS, basic (₹) | 13.36 | 11.01 | +21.3% | 6.26 | +113.4% |
| Net margin (%) | 15.0 | 14.1 | 8.7 |
Standalone
- Filed with BSE
- 28 Jul 2023, 18:45 IST
- Board meeting
- 28 Jul 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE